246
Views
12
CrossRef citations to date
0
Altmetric
Research Article

Sustained release of low molecular weight heparin from PLGA microspheres prepared by a solid-in-oil-in-water emulsion method

, , , &
Pages 763-770 | Received 06 Apr 2011, Accepted 19 Sep 2011, Published online: 31 Oct 2011

References

  • Cadene M, Boudier C, de Marcillac GD, Bieth JG. Influence of low molecular mass heparin on the kinetics of neutrophil elastase inhibition by mucus proteinase inhibitor. J Biol Chem 1995; 270: 13204–9
  • Cleland JL, Jones JS. Stable formulations of recombinant human growth hormone and interferon-gama for microencapsulation in biodegradable microspheres. Pharm Res 1996; 13: 1464–75
  • Dal Pozzo A, Acquasaliente M, Geron MR, Andriuoli G. New heparin complexes active by intestinal absorption: I-multiple ion pairs with basic organic compounds. Thromb Res 1989; 56: 119–24
  • Han K, Lee KD, Gao ZhG, Park JS. Preparation and evaluation of poly(l-lactic acid) microspheres containing rhEGF for chronic gastric ulcer healing. J Control Release 2001; 75: 259–69
  • He JT, Su HB, Li GP, Tao XM, Mo W, Song HY. Stabilization and encapsulation of a staphylokinase variant (K35R) into poly(lactic-co-glycolic acid) microspheres. Int J Pharm 2006; 309: 101–8
  • Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114: 489S–510S
  • Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(1 Suppl)64S–94S
  • Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 188S–203S
  • Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release 2006; 113: 38–42
  • Kreitz MR, Domm JA, Mathiowitz E. Controlled delivery of therapeutics from microporous membranes. II. In vitro degradation and release of heparin-loaded poly(D,L-lactide-co-glycolide). Biomaterials 1997; 18: 1645–51
  • Lanke SSS, Kolli CS, Strom JG, Banga AK. Enhanced transdermal delivery of low molecular weight heparin by barrier perturbation. Int J Pharm 2009; 365: 26–33
  • Luan X, Skupin M, Siepmann J, Bodmeier R. Key parameters affecting the initial release (burst) and encapsulation efficiency of peptide-containing poly(lactide-co-glycolide) microparticles. Int J Pharm 2006; 324: 168–75
  • Morita T, Horikiri Y, Yamahara H, Suzuki T, Yoshino H. Formation and isolation of spherical fine protein microparticles through lyophilization of protein-poly(ethylene glycol) aqueous mixture. Pharm Res 2000a; 17: 1367–73
  • Morita T, Sakamura Y, Horikiri Y, Suzuki T, Yoshino H. Protein encapsulation into biodegradable microspheres by a novel s/o/w emulsion method using poly(ethylene glycol) as a protein micronization adjuvant. J Control Release 2000b; 69: 435–44
  • Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release 2008; 125: 193–209
  • Rawat A, Majumder QH, Ahsan F. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J Control Release 2008; 128: 224–32
  • Wang HJ, Lin ZX, Liu XM, Sheng SY, Wang JY. Heparin-loaded zein microsphere film and hemocompatibility. J Control Release 2005; 105: 120–31
  • Weitz JL. Low-molecular-weight heparins. New Engl J Med 1997; 337: 688–98
  • Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm 2008; 364: 298–327
  • Yang T, Hussain A, Bai S, Khalil IA, Harashima H, Ahsan F. Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin. J Control Release 2006; 115: 289–97
  • Yang Z, Birkenhauer P, Julmy F, Chickering D, Ranieri JP, Merkle HP, Lüscher TF, Gander B. Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation. J Control Release 1999; 60: 269–77

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.